EFFICACY AND SAFETY OF CHROMIUM AS A THERAPEUTIC INTERVENTION

铬作为治疗干预措施的功效和安全性

• 批准号: 7950787
• 负责人: DENNIS C MYNARCIK
• 金额: $ 1.6万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950787
• 关键词: Chromium; Chromium Picolinate; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Disease; Epidemic; Funding; Grant; Incidence; Institution; Insulin Resistance; Liver; Monitor; Morbidity - disease rate; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Patients; Pharmaceutical Preparations; Renal function; Research; Research Personnel; Resources; Safety; Source; Supplementation; Therapeutic Intervention; Toxic effect; United States National Institutes of Health; dietary supplements; improved; insulin sensitivity; mortality; oxidative damage; placebo controlled study; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The level of obesity has reached epidemic proportions [1] and contributes to increased mortality and morbidity [2]. Part of both mortality and morbidity arises from an increased incidence of insulin resistance and diabetes. However, it is possible to prevent progression to diabetes. A recent study has shown that when patients with insulin resistance were treated prior to the development of diabetes, there was a dramatic decrease in the number of subjects who went on to develop the disease [3]. Although several conventional drugs are effective in treating the insulin resistance associated with type 2 diabetes mellitus, the dietary supplement chromium picolinate has also been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus[4]. Intriguingly, chromium is comparatively inexpensive and apparently well-tolerated [4]. Specific Aim 1 of this proposal will examine the safety and efficacy of supplemental chromium picolinate in the treatment of insulin resistance in obesity-related insulin resistance. We will assess improvements in insulin sensitivity in a placebo-controlled study of chromium supplementation over a two-month course of therapy. We will also assess the safety of chromium picolinate treatment. Parameters of liver, renal function and oxidative damage will be monitored for possible chromium-related toxicities.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 肥胖程度已达到流行病的程度[1]，并导致死亡率和发病率增加[2]。 部分死亡率和发病率是由胰岛素抵抗和糖尿病发病率增加引起的。 然而，预防进展为糖尿病是可能的。 最近的一项研究表明，如果胰岛素抵抗患者在发展为糖尿病之前接受治疗，则继续发展该疾病的受试者数量会急剧减少[3]。 尽管几种常规药物可有效治疗与 2 型糖尿病相关的胰岛素抵抗，但膳食补充剂吡啶甲酸铬也被证明可以改善 2 型糖尿病患者的胰岛素敏感性[4]。 有趣的是，铬相对便宜并且耐受性良好[4]。 该提案的具体目标 1 将检查补充吡啶甲酸铬在治疗肥胖相关胰岛素抵抗中的安全性和有效性。 我们将在一项为期两个月的铬补充剂安慰剂对照研究中评估胰岛素敏感性的改善情况。 我们还将评估吡啶甲酸铬治疗的安全性。 将监测肝脏、肾功能和氧化损伤的参数，以发现可能的铬相关毒性。